Biomea Fusion Q2 2023: positive diabetes & AML data; net loss widens

Biomea Fusion, Inc.

2023-Q2 EPS reported -$1.66

Diabetes: in Cohort 3 (100 mg BMF-219 QD), mean HbA1c reduction of 1.49% at Week 12, 62% greater than at end of 4-week dosing.
60% of Cohort 3 patients achieved HbA1c ≤7% at Week 12 vs 30% at Week 4; no severe TEAEs off treatment.
Oncology: 2 complete responses out of 5 relapsed/refractory AML patients carrying menin-dependent mutations at Dose Level 4.
Cash $223.3M as of June 30, 2023; net loss $24.9M in Q2 2023 vs $17.3M in Q2 2022.
Initiated Phase I for BMF-500 (COVALENT-103), a third-generation covalent FLT3 inhibitor.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biomea Fusion, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On July 31, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Biomea Fusion, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-035939

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.